DANBURY, Conn., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the third fiscal quarter ended June 30, 2012. Highlights since beginning of third fiscal quarter
- Completion of $18.5 million financing with institutional investors.
- Obtained exclusive license to Aegis Therapeutics' technologies for development and commercialization of glucagon pharmaceutical formulations.
- Liquid formulation of glucagon for the treatment of severe hypoglycemia remains on track for projected NDA submission in early 2014.
- Presented positive Phase 1 clinical data at the American Diabetes Association 72 nd Scientific Sessions for lead recombinant human insulin-based ultra-rapid-acting candidates BIOD-123 and BIOD-125; BIOD-123 on track for advancement into Phase 2 clinical trial this quarter with top line data projected for third calendar quarter of 2013.
- Analog-based ultra-rapid-acting insulin remains on target for top line Phase 1 data in first calendar quarter of 2013.
- Awarded NIH grant of $582,473 to develop concentrated ultra-rapid-acting insulin formulations for use in artificial pancreas.
- Regained compliance with NASDAQ minimum bid price listing requirement.
Research and development expenses were $3.0 million for the three months ended June 30, 2012, compared to $2.9 million for the same period in the prior year.General and administrative expenses were $1.8 million for the three months ended June 30, 2012, compared to $2.4 million for the same period in the prior year. The decrease in general and administrative expenses was primarily attributable to lower stock-based compensation expense. Expenses for the three months ended June 30, 2012 and 2011 included costs of $0.3 million and $1.3 million, respectively, in stock-based compensation expense related to options granted to employees and non-employee directors. In addition, the results for the three months ended June 30, 2012 and 2011 included an increase of $1.4 million and a decrease of $1.4 million, respectively, in the fair value of the company's common stock warrant liability. Biodel did not recognize any revenue during the three months ended June 30, 2012 or 2011. On June 11, 2012, the company effected a one-for-four reverse split of its outstanding common stock and fixed on a post-split basis the number of authorized shares of its common stock at 25,000,000 (reduced from 100,000,000 authorized shares). As a result of the reverse stock split, each share of the company's common stock outstanding at the effective time was automatically changed into one-quarter of a share of common stock. Also as a result of the reverse stock split, the number of shares of common stock subject to outstanding options restricted stock units and warrants issued by the company and the number of shares reserved for future issuance under the company's stock plans were reduced by a factor of four. On June 27, 2012, the company completed a private placement of an aggregate of 4,250,020 shares of the company's common stock, 3,605,607 shares of the company's series B convertible preferred stock and warrants to purchase an aggregate of 2,749,469 shares of its common stock at an exercise price of $2.66 per share. The company received net proceeds, after deducting placement agents' fees and other transaction expenses, of approximately $17.2 million from the 2012 private placement.
At June 30, 2012, Biodel had cash and cash equivalents of $43.7 million and 14.0 million and 5.4 million shares of common stock and convertible preferred stock outstanding, respectively.Conference Call and Webcast Information Biodel's senior management will host a conference call on August 8, 2012 beginning at 5:00 p.m. Eastern Daylight Time to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing +1 (877) 303-8028 (United States) or +1 (760) 536-5167 (international). To access the call by live audio webcast, please log on to the investor section of the company's website at www.biodel.com . An archived version of the audio webcast will be available on Biodel's website. Interested parties may also access an audio replay by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference ID number 15900969. About Biodel Inc. Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Safe-Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes and our liquid formulation of glucagon that is intended to treat patients experiencing severe hypoglycemia; our ability to advance a proprietary insulin formulation into a Phase 2 clinical trial in a timely manner, and the outcome of that trial; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a liquid formulation of glucagon; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a liquid formulation of glucagon; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended March 31, 2012. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
|(A Development Stage Company)|
|Consolidated Condensed Balance Sheets|
|(in thousands, except share and per share amounts)|
|September 30,||June 30,|
|Cash and cash equivalents||$38,701||$43,691|
|Prepaid and other assets||399||416|
|Total current assets||39,196||45,201|
|Property and equipment, net||2,253||1,662|
|Intellectual property, net||49||47|
|Long term other assets||7||—|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Clinical trial expenses||763||427|
|Payroll and related||1,118||1,113|
|Accounting and legal fees||191||287|
|Income taxes payable||103||73|
|Total current liabilities||3,289||2,768|
|Common stock warrant liability||996||7,182|
|Other long term liabilities||142||—|
|Preferred stock, $.01 par value; 50,000,000 shares authorized, 1,813,944 and 5,419,551 issued and outstanding||18||54|
|Common stock, $.01 par value; 25,000,000 shares authorized; 9,661,868 and 13,982,826 issued and outstanding||96||140|
|Additional paid-in capital||212,310||226,980|
|Deficit accumulated during the development stage||(175,346)||(190,214)|
|Total stockholders' equity||37,078||36,960|
|Total liabilities and stockholders' equity||$41,505||$46,910|
|(A Development Stage Company)|
|Consolidated Condensed Statements of Operations and Comprehensive Loss|
|(in thousands, except share and per share amounts)|
|Three Months Ended||Nine Months Ended||(inception) to|
|June 30,||June 30,||June 30,|
|Research and development||2,941||2,956||11,349||7,952||138,081|
|General and administrative||2,382||1,776||7,264||5,626||62,572|
|Total operating expenses||5,323||4,732||18,613||13,578||200,653|
|Other (income) and expense:|
|Interest and other income||(20)||(15)||(30)||(56)||(5,622)|
|Adjustment to fair value of common stock warrant liability||(1,355)||1,355||(3,890)||1,354||(10,003)|
|Loss on settlement of debt||—||—||—||—||627|
|Operating loss before tax provision (benefit)||(3,948)||(6,072)||(14,693)||(14,876)||(185,733)|
|Tax provision (benefit)||26||(21)||32||(8)||(579)|
|Net loss and other comprehensive loss||(3,974)||(6,051)||(14,725)||(14,868)||(185,154)|
|Charge for accretion of beneficial conversion rights||—||—||—||—||(603)|
|Deemed dividend — warrants||—||—||—||—||(4,457)|
|Net loss and other comprehensive loss applicable to common stockholders||$ (3,974)||$ (6,051)||$ (14,725)||$ (14,868)||$ (190,214)|
|Net loss and other comprehensive loss per share — basic and diluted||$ (0.48)||$ (0.52)||$ (2.06)||$ (1.44)|
|Weighted average shares outstanding — basic and diluted||8,254,413||11,600,003||7,158,806||10,320,558|
CONTACT: Seth D. Lewis, +1-646-378-2952